Literature DB >> 21958853

Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells.

Shuntaro Oka1, Hiroyuki Okudaira, Yasunori Yoshida, David M Schuster, Mark M Goodman, Yoshifumi Shirakami.   

Abstract

INTRODUCTION: We investigated the mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid (anti-[(14)C]FACBC) transport by human-derived prostate cancer (PCa) cells and normal human prostatic epithelial cells (PrECs).
METHODS: Using PCa cells (DU145, PC-3, LNCaP) and PrECs, we performed the following in vitro experiments: time-course, kinetics, competitive inhibition by synthetic/naturally occurring amino acids (AAs), exchange transport with synthetic/naturally occurring AAs and pH-dependency of anti-[(14)C]FACBC uptake. We also examined the amino acid transporter (AAT) expression using flow cytometry.
RESULTS: The uptake of anti-[(14)C]FACBC by LNCaP and DU145 cells was higher than that by PC-3 and PrECs. The K(m) values for anti-[(14)C]FACBC were 64.4 and 191.7 μmol/L in the DU145 cells and PrECs, respectively. Total levels of anti-[(14)C]FACBC uptake were positively correlated with the expression level of system ASC in PCa cells. The contributions of Na(+)-dependent AATs to anti-[(14)C]FACBC uptake were greater than those of Na(+)-independent AATs, especially in PCa cells. In the presence of Na(+), glutamine and serine showed the strongest inhibitory effect against anti-[(14)C]FACBC uptake, suggesting that system ASC, especially ASCT2, is an important AAT for anti-[(14)C]FACBC. In contrast, phenylalanine and 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid, but not N-ethylmaleimide, almost completely inhibited the anti-[(14)C]FACBC uptake in the absence of Na(+), indicating the contribution of LAT1. In the exchange transport experiments, glutamine showed the strongest transstimulation of intracellular anti-[(14)C]FACBC efflux in DU145 cells. Furthermore, the contributions of Na(+)-independent AATs to the uptake of anti-[(14)C]FACBC in DU145 and PrECs were greater under acidic pH conditions than under neutral or alkaline pH conditions.
CONCLUSIONS: Total uptake of anti-[(14)C]FACBC by PCa cells correlates with the expression level of system ASC in PCa cells. Furthermore, LAT1 is an important transport system for anti-[(14)C]FACBC uptake, especially in an acidic environment, such as the intra-tumoural environment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958853     DOI: 10.1016/j.nucmedbio.2011.06.008

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  35 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

4.  Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.

Authors:  Oladunni O Akin-Akintayo; Ashesh B Jani; Oluwaseun Odewole; Funmilayo I Tade; Peter T Nieh; Viraj A Master; Leah M Bellamy; Raghuveer K Halkar; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

5.  18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

Authors:  Kirsten M Selnæs; Brage Krüger-Stokke; Mattijs Elschot; Frode Willoch; Øystein Størkersen; Elise Sandsmark; Siver A Moestue; May-Britt Tessem; Dag Halvorsen; Eirik Kjøbli; Anders Angelsen; Sverre Langørgen; Helena Bertilsson; Tone F Bathen
Journal:  Eur Radiol       Date:  2018-01-02       Impact factor: 5.315

6.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

7.  Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts.

Authors:  F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster
Journal:  Amino Acids       Date:  2018-06-15       Impact factor: 3.520

8.  Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.

Authors:  Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

9.  Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.

Authors:  Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-17       Impact factor: 9.236

10.  Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.

Authors:  David M Schuster; Pooneh A Taleghani; Peter T Nieh; Viraj A Master; Rianot Amzat; Bital Savir-Baruch; Raghuveer K Halkar; Tim Fox; Adeboye O Osunkoya; Carlos S Moreno; Jonathon A Nye; Weiping Yu; Baowei Fei; Zhibo Wang; Zhengjia Chen; Mark M Goodman
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.